Acute megakaryoblastic leukemia
MONDO:0018872Acute megakaryoblastic leukemia (AMKL) is a form of acute myeloid leukemia (AML) that occurs predominantly in childhood and particularly in children with Down syndrome (DS-AMKL). Nonspecific symptoms may be irritability, weakness, and dizziness while specific symptoms include pallor, fever, mucocutaneous bleeding, hepatosplenomegaly, neurological manifestations and rarely lymphadenopathy. Acute panmyelosis with myelofibrosis may also be associated with AMKL. In contrast to DS-AMKL (around 80 % survival), non-DS-AMKL is an AML subgroup associated with poor prognosis.
Also known as: AMKL, AML M7, FAB M7, acute M7 myeloid leukaemia, acute M7 myeloid leukemia, acute megakaryoblastic leukaemia (FAB type M7), acute megakaryoblastic leukemia, acute megakaryoblastic leukemia (FAB type M7)
3088 clinical trials for this condition and its sub-types, 5 tagged with Acute megakaryoblastic leukemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Acute megakaryoblastic leukemia
-
Can a Platelet-Boosting drug speed recovery for older leukemia patients?
Disease control CompletedThis phase II trial investigates whether eltrombopag, a drug that stimulates platelet production, can help older adults with acute myeloid leukemia (AML) recover their platelet counts faster after initial chemotherapy. Older patients often experience slow platelet recovery, which…
Phase 2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Could a targeted drug keep AML in check?
Disease control CompletedThis phase III trial tests whether the drug tipifarnib can prevent acute myeloid leukemia (AML) from coming back in patients who are already in remission. Participants include adults over 60 in first remission, those in second or later remission, or those who achieved remission a…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
High-Dose therapy plus stem cell transplant shows promise for AML patients
Disease control CompletedThis phase 2 trial tested a treatment for adults with acute myeloid leukemia (AML) in first remission. Patients received high-dose chemotherapy and radiation to kill cancer cells, followed by an autologous stem cell transplant (using their own stem cells) to restore blood cell pr…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC